ArticleCancers2025

Trends in Efficacy Endpoints in Phase II Glioblastoma Trials: A Regulatory Science Analysis (FY2020-FY2022).

Shinya Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.